Articles with public access mandates - Mansoor Raza MirzaLearn more
Not available anywhere: 3
Gynecologic Cancer InterGroup (GCIG) consensus review for carcinoid tumors of the ovary
NS Reed, E Gomez-Garcia, D Gallardo-Rincon, B Barrette, K Baumann, ...
International Journal of Gynecologic Cancer 24 (Supp 3), 2014
Mandates: US National Institutes of Health
Comparative assessment of diagnostic homologous recombination deficiency–associated mutational signatures in ovarian cancer
Z Sztupinszki, M Diossy, J Borcsok, A Prosz, N Cornelius, MK Kjeldsen, ...
Clinical Cancer Research 27 (20), 5681-5687, 2021
Mandates: US Department of Defense, Danish Council for Independent Research
Patterns of treatment failure in patients undergoing adjuvant or definitive radiotherapy for vulvar cancer
CS Vorbeck, A Jhingran, RB Iyer, A Loft, A Klopp, MR Mirza, ...
International Journal of Gynecologic Cancer 29 (5), 2019
Mandates: US National Institutes of Health
Available somewhere: 18
ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up
N Colombo, C Creutzberg, F Amant, T Bosse, A González-Martín, ...
International Journal of Gynecologic Cancer 26 (1), 2016
Mandates: Research Foundation (Flanders)
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
N Colombo, C Sessa, A du Bois, J Ledermann, WG McCluggage, ...
Annals of oncology 30 (5), 672-705, 2019
Mandates: US Department of Defense
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
AM Oza, AD Cook, J Pfisterer, A Embleton, JA Ledermann, ...
The Lancet Oncology 16 (8), 928-936, 2015
Mandates: UK Medical Research Council, National Institute for Health Research, UK
Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
A Oaknin, TJ Bosse, CL Creutzberg, G Giornelli, P Harter, F Joly, ...
Annals of oncology 33 (9), 860-877, 2022
Mandates: US National Institutes of Health
Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: recurrent disease
MK Wilson, E Pujade-Lauraine, D Aoki, MR Mirza, D Lorusso, AM Oza, ...
Annals of Oncology 28 (4), 727-732, 2017
Mandates: US National Institutes of Health
First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors
AR Abdul Razak, M Mau-Soerensen, NY Gabrail, JF Gerecitano, ...
Journal of Clinical Oncology 34 (34), 4142-4150, 2016
Mandates: US National Institutes of Health
Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer
MR Stockler, F Hilpert, M Friedlander, MT King, L Wenzel, CK Lee, F Joly, ...
Journal of Clinical Oncology 32 (13), 1309-1316, 2014
Mandates: US National Institutes of Health
Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo …
XH Wu, JQ Zhu, RT Yin, JX Yang, JH Liu, J Wang, LY Wu, ZL Liu, YN Gao, ...
Annals of Oncology 32 (4), 512-521, 2021
Mandates: National Natural Science Foundation of China
MILO/ENGOT-ov11: binimetinib versus physician’s choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum
BJ Monk, RN Grisham, S Banerjee, E Kalbacher, MR Mirza, I Romero, ...
Journal of clinical oncology 38 (32), 3753-3762, 2020
Mandates: US National Institutes of Health
European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer
I Vergote, A González-Martín, I Ray-Coquard, P Harter, N Colombo, ...
Annals of Oncology 33 (3), 276-287, 2022
Mandates: Cancer Research UK, National Institute for Health Research, UK
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup
I Vergote, A Gonzalez-Martin, D Lorusso, C Gourley, MR Mirza, JE Kurtz, ...
The Lancet Oncology 23 (8), e374-e384, 2022
Mandates: US National Institutes of Health, Health Research Board, Ireland, National …
A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer
CK Lee, RJ Simes, C Brown, V Gebski, J Pfisterer, AM Swart, ...
Annals of oncology 24 (4), 937-943, 2013
Mandates: UK Medical Research Council
Combining conventional therapy with immunotherapy: a risky business?
A Coosemans, A Vankerckhoven, T Baert, L Boon, H Ruts, M Riva, ...
European Journal of Cancer 113, 41-44, 2019
Mandates: National Institute for Health Research, UK
Patterns of care for radiotherapy in vulvar cancer: a Gynecologic Cancer Intergroup study
DK Gaffney, A Du Bois, K Narayan, N Reed, T Toita, S Pignata, P Blake, ...
International Journal of Gynecologic Cancer 19 (1), 2009
Mandates: US National Institutes of Health
VP7-2022: An ad-hoc interim overall survival results of niraparib with individualized starting dose as maintenance therapy in patients with platinum-sensitive recurrent ovarian …
MR Mirza, X Wu, J Zhu, R Yin, J Yang, J Liu, J Wang, L Wu, Z Liu, Y Gao, ...
Annals of Oncology 34 (1), 124-125, 2023
Mandates: National Natural Science Foundation of China
596 A randomised phase II study of nintedanib (BIBF1120) compared to chemotherapy in patients with recurrent clear cell carcinoma of the ovary or endometrium.(NICCC/ENGOT-OV36)
R Glasspool, I Mcneish, A Westermann, S Hinsley, J Ledermann, ...
International Journal of Gynecologic Cancer 30 (Suppl 4), 2020
Mandates: Cancer Research UK
Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous …
MR Mirza, G Lindahl, S Mahner, A Redondo, M Fabbro, BJ Rimel, ...
Cancer research communications 2 (11), 1436-1444, 2022
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program